9,10-anhydroadriamycin
less active than parent cpd against human lymphoblastic leukemia cells in culture
Also Known As:
9,10-anhydrodoxorubicin; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-9,10-dihydro-6,11-dihydroxy-8-(hydroxyacetyl)-1-methoxy-, (S)-
Networked: 0
relevant articles (0 outcomes,
0 trials/studies)
Bio-Agent Context: Research Results